Rice Hall James & Associates LLC Has $28.57 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Rice Hall James & Associates LLC lessened its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 4.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 998,625 shares of the company's stock after selling 44,915 shares during the period. Pacira BioSciences comprises 1.7% of Rice Hall James & Associates LLC's investment portfolio, making the stock its 13th largest holding. Rice Hall James & Associates LLC owned about 2.15% of Pacira BioSciences worth $28,571,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ICA Group Wealth Management LLC acquired a new stake in Pacira BioSciences during the 4th quarter worth about $30,000. GAMMA Investing LLC raised its holdings in Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock worth $38,000 after buying an additional 932 shares during the period. Park Place Capital Corp acquired a new position in shares of Pacira BioSciences in the 2nd quarter valued at about $46,000. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences in the 2nd quarter valued at about $50,000. Finally, nVerses Capital LLC increased its holdings in shares of Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock valued at $51,000 after purchasing an additional 1,600 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Insider Activity at Pacira BioSciences

In related news, CEO Frank D. Lee acquired 8,264 shares of the company's stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the purchase, the chief executive officer now directly owns 107,784 shares of the company's stock, valued at approximately $1,304,186.40. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Frank D. Lee acquired 8,264 shares of the company's stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the purchase, the chief executive officer now directly owns 107,784 shares of the company's stock, valued at approximately $1,304,186.40. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jonathan Slonin sold 2,836 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the transaction, the insider now owns 95,557 shares of the company's stock, valued at $2,699,485.25. The disclosure for this sale can be found here. Over the last ninety days, insiders bought 11,176 shares of company stock worth $136,240 and sold 13,113 shares worth $363,906. 6.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Barclays downgraded Pacira BioSciences from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $38.00 to $25.00 in a report on Wednesday, July 3rd. Royal Bank of Canada cut Pacira BioSciences from an "outperform" rating to a "sector perform" rating and lowered their price target for the company from $37.00 to $14.00 in a research note on Monday, August 12th. HC Wainwright lowered their price target on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a research note on Monday, August 12th. Truist Financial cut Pacira BioSciences from a "buy" rating to a "sell" rating and lowered their price target for the company from $30.00 to $8.00 in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. reissued an "underweight" rating and issued a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $24.78.

Pacira BioSciences Stock Performance

Shares of PCRX traded down $0.25 during mid-day trading on Wednesday, hitting $13.00. The company's stock had a trading volume of 707,333 shares, compared to its average volume of 875,892. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82. The firm has a market capitalization of $599.69 million, a PE ratio of 9.27 and a beta of 0.84. The stock's 50-day moving average is $17.67 and its two-hundred day moving average is $24.84.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.11. The company had revenue of $178.02 million during the quarter, compared to analysts' expectations of $173.31 million. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.24 EPS for the current year.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.